Nanjing Jiqun Pharmaceutical Technology Co., Ltd. is an innovative biopharmaceutical enterprise specializing in new drug research and development, technology transfer, technical services and industrialization of new pharmaceutical products. The company was founded in 2013 and is located in the beautiful ancient city of Nanjing. There are many universities nearby and there are rich scientific research resources.
1. Innovative drug development
Jiqun Pharmaceutical is committed to the research and development of innovative drugs and strives to become an innovative biopharmaceutical company with a leading position in the fields of obstetrics and gynecology, oncology and metabolic diseases! The innovative products that have been deployed include: prevention and treatment of gynecological hemorrhage and promotion of Third stage of labor management, drugs to promote postpartum functional recovery, gynecological oncology drugs, dysmenorrhea and uterine smooth muscle antispasmodic drugs, as well as gynecological inflammation treatment drugs, oral drugs for morning sickness, etc., are all first-of-its-kind drugs or first-of-its-kind drugs that fill the gap; At the same time, it also has a global layout in the research of new small molecule entity drugs and the development of gene therapy drugs.
2. Technology transfer and technical services
The company provides a series of drug development technical services including synthesis process development, preparation formulation and process development, drug consistency evaluation, packaging material compatibility research, pharmaceutical research, druggability evaluation, sample analysis, registration and clinical research. At the same time, the company focuses on the research and development of innovative drugs, with 9 innovative drugs and more than 40 specialty generic drugs in its existing R&D pipeline. The company focuses on the construction of R&D platforms, continues to introduce advanced drug R&D technologies at home and abroad, and gradually forms a series of R&D platforms with characteristics and technical advantages, such as the new drug delivery system DDS-oral quick-dissolving film and sublingual drug delivery technology development platform. Engineering technology and industrialization platform for alkaloid series derivatives, drug consistency evaluation technology platform, packaging material compatibility research technology platform, etc.
3. MAH and technical cooperation
As of December 31, 2019, the company has obtained clinical approval documents for 3 new drugs (including APIs), and 8 new drugs are in the application stage. He has applied for more than 50 invention patents and is listed on the National Equities Exchange and Quotations (NEEQ). Under the framework of the new version of the Drug Administration Law, we are committed to improving the quality of improved new drugs and generic drugs. Currently, we have a number of high-end products that are about to be put on the market! We have a rich reserve of products under development. We welcome cooperation with those with production and marketing capabilities. Partners, jointly develop the market and serve the public!
4. Development of platform technology
In line with the philosophy of "innovation, people-oriented, excellence, and teamwork", the company continues to develop and improve its business capabilities, and establish an efficient new drug project management system and a complete new drug project research and development system. In terms of platform technology development, we are committed to new drug application technology, new drug delivery technology, new key technologies to improve drug absorption characteristics, new dosage forms, new routes, new usages, new compound formulas and other improved new drug research platforms, complex dosage forms and Research efforts have been intensified in aspects such as sustained and controlled release technology, with remarkable results. It is a leader in the field of non-viral vector gene delivery drugs.
Drive the integration of pharmaceutical industry resources through innovation, continue to serve patients' health, create value for customers, and bring returns to shareholders!